{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "622 women with clinical stage 2\u20133 estrogen receptor-positive (ER+) BC were enrolled"
      },
      "Participants": {
        "score": 2,
        "evidence": "622 women with clinical stage 2\u20133 estrogen receptor-positive (ER+) BC were enrolled"
      },
      "Intervention": {
        "score": 2,
        "evidence": "ability of three neoadjuvant aromatase inhibitors (NAIs) to reduce residual disease"
      },
      "Objective": {
        "score": 1,
        "evidence": "to assess whether switching to neoadjuvant chemotherapy (NCT) after 4 weeks on NAI with Ki67 > 10% increases pathologic complete response (pCR)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Five-year cumulative incidence rate for LRR is estimated to be 1.53% (95% CI: 0.7 to 3.0%)"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "622 women with clinical stage 2\u20133 estrogen receptor-positive (ER+) BC were enrolled"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The analysis cohort consisted of 509 patients"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Five-year cumulative incidence rate for LRR is estimated to be 1.53% (95% CI: 0.7 to 3.0%)"
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}